The direct costs of HIV/AIDS care

Area of Science:

• Public Health
• Health Economics
• Infectious Disease Management

Background:

• Highly active antiretroviral therapy (HAART) has transformed HIV/AIDS treatment.
• Accurate estimation of direct medical costs is crucial for healthcare planning and resource allocation.
• Previous studies on HIV treatment costs show significant variability.

Purpose of the Study:

• To review and synthesize published data on the direct medical costs of treating HIV-infected individuals on HAART.
• To identify challenges in comparing cost data across different studies.
• To assess the implications of HAART on HIV treatment expenditures.

Main Methods:

• Systematic review of published literature reporting direct medical costs for HIV treatment.
• Screening of 543 potentially relevant studies, with nine selected for detailed analysis.
• Analysis focused on identifying cost drivers and methodological differences between studies.

Main Results:

• Only a small fraction of reviewed studies provided adequate data for cost analysis.
• Patients with more advanced HIV disease incurred higher direct medical costs.
• Significant heterogeneity in study components, populations, cost estimation methods, and reporting levels precluded valid cross-study comparisons.

Conclusions:

• The advent of HAART significantly impacts the direct medical costs of HIV treatment.
• There is a critical need for more standardized and comprehensive studies on HIV treatment costs.
• Computer simulation presents a promising method for estimating resource use and costs in HIV management.